Novartis
Itvisma
spinal muscular atrophy (SMA)
Resolved
5days ago
Approval decision · Jul 2, 2026
What's at stake
A final FDA approval decision on Itvisma for spinal muscular atrophy (SMA) is expected Jul 2, 2026.
Primary source
· Press release
verified 17h ago
“Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA) July 02, 2026 01:00 ET| Source: Novartis Pharma AG”